{
  "ticker": "BGT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968788",
  "id": "02968788",
  "pages": 37,
  "price_sensitive": false,
  "date": "20250711",
  "time": "1759",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250711/pdf/06lqr36kj6l5yc.pdf",
  "summary": "### **Material Information Summary \u2013 Options Prospectus**  \n\n#### **Key Details:**  \n- **Issuer:** Bio-Gene Technology Limited (ASX: BGT)  \n- **Instrument Offered:** 95,352,788 Placement Options (comprising 47,676,394 **2028 Options** and 47,676,394 **2030 Options**).  \n- **Exercise Prices & Expiry:**  \n  - 2028 Options: **A$0.034**, expiring **15 May 2028**.  \n  - 2030 Options: **A$0.046**, expiring **15 May 2030**.  \n- **Conditions:**  \n  - Issue of Options is **conditional on shareholder approval** at an EGM scheduled for **14 July 2025**.  \n  - Expected grant date: **15 July 2025** (within 5 days of EGM approval).  \n- **Purpose:**  \n  - Facilitate issuance of 92,302,176 Options to Placement Participants (1x 2028 + 1x 2030 Option per 2 Shares subscribed in Placement).  \n  - Issue 3,050,612 Options (1,525,306 of each type) to Lead Manager (Stralis Capital) as consideration for services.  \n  - **No funds raised upfront**; potential future proceeds of **~A$3.8M** if all Options exercised.  \n\n#### **Capital Structure Impact (Pro Forma):**  \n- **Existing Shares:** 266,419,324.  \n- **Placement Shares (if full Placement):** 41,961,784.  \n- **Total Options Post-Issue:**  \n  - 2028 Options: 55,035,075.  \n  - 2030 Options: 55,035,075.  \n- **Potential Dilution:**  \n  - ~23.6% dilution if all Placement Options exercised.  \n  - ~26.3% dilution if all Options (including SPP) exercised.  \n\n#### **Timetable:**  \n- **Lodgment with ASIC:** 11 July 2025.  \n- **EGM Date:** 14 July 2025.  \n- **Expected Issue Date:** 15 July 2025.  \n- **Holding Statements Despatched:** 16 July 2025.  \n\n#### **Additional Material Points:**  \n- **No ASX Quotation:** Options **will not be listed** on ASX or any exchange.  \n- **Use of Funds (if exercised):** General working capital (no specific allocation).  \n- **Risks Highlighted:** Speculative nature of investment, dilution, regulatory hurdles in insecticide development, and reliance on future funding.  \n\n**Conclusion:** Focus on shareholder approval (14 July) and potential dilution impact. No immediate liquidity or capital raise; future cash inflow contingent on option exercise.  \n\n**Format Note:** Excluded boilerplate, risk details (already summarized), and non-material operational updates.",
  "usage": {
    "prompt_tokens": 18080,
    "completion_tokens": 622,
    "total_tokens": 18702,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-11T08:59:19.853654"
}